Ikena Oncology, Inc.
IKNA
Cena:
Valuace
70
Růst
53
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
INMAGENE BIOPHARMACEUTICALS ANNOUNCES COMPLETION OF MERGER WITH IKENA ONCOLOGY AND CONCURRENT PRIVATE PLACEMENT OF $75 MILLION
25-07-2025
THE COMBINED COMPANY WILL OPERATE UNDER THE NAME “IMAGENEBIO, INC.” AND WILL BEGIN TRADING ON NA...
Více zde
IKENA ONCOLOGY AND INMAGENE BIOPHARMACEUTICALS ANNOUNCE KRISTIN YAREMA, PH.D., AS CHIEF EXECUTIVE OFFICER OF MERGED COMPANY
23-07-2025
BOSTON AND SAN DIEGO, JULY 23, 2025 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA) (“IKEN...
Více zde
IKENA ONCOLOGY ANNOUNCES STOCKHOLDER APPROVAL OF MERGER WITH INMAGENE BIOPHARMACEUTICALS
15-07-2025
COMBINED COMPANY TO TRADE ON NASDAQ UNDER TICKER “IMA” IKENA ANNOUNCES 1-FOR-12 REVERSE STOCK SP...
Více zde
IKENA ONCOLOGY ANNOUNCES ISS AND GLASS LEWIS RECOMMEND STOCKHOLDERS VOTE “FOR” PROPOSED MERGER WITH INMAGENE BIOPHARMACEUTICALS
11-07-2025
BOSTON, JULY 11, 2025 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA,” THE “CO...
Více zde
IKENA ONCOLOGY AND INMAGENE BIOPHARMACEUTICALS ANNOUNCE AGREEMENT FOR MERGER AND PRIVATE PLACEMENT
23-12-2024
INMAGENE BIOPHARMACEUTICALS IS A CLINICAL STAGE COMPANY FOCUSED ON DEVELOPING IMG-007, A NON-DEPLETI...
Více zde
IKENA ONCOLOGY AND INMAGENE BIOPHARMACEUTICALS ANNOUNCE AGREEMENT FOR MERGER AND PRIVATE PLACEMENT
23-12-2024
INMAGENE BIOPHARMACEUTICALS IS A CLINICAL STAGE COMPANY FOCUSED ON DEVELOPING IMG-007, A NON-DEPLETI...
Více zde
IKENA ONCOLOGY REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
07-11-2024
STRONG FINANCIAL POSITION WITH $138 MILLION IN CASH AND INVESTMENTS AT CLOSE OF THIRD QUARTER STRONG...
Více zde
IKENA ONCOLOGY REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
08-08-2024
STRONG FINANCIAL POSITION WITH $145 MILLION IN CASH AND INVESTMENTS AT CLOSE OF SECOND QUARTER STRON...
Více zde
UPDATE – IKENA ONCOLOGY ANNOUNCES STRATEGIC UPDATE
28-05-2024
IKENA TO DISCONTINUE DEVELOPMENT OF IK-930 IK-595 DOSE ESCALATION CONTINUES IN RAS AND RAF MUTANT CA...
Více zde
IKENA ONCOLOGY ANNOUNCES STRATEGIC UPDATE
28-05-2024
IKENA TO DISCONTINUE DEVELOPMENT OF IK-930 IK-595 DOSE ESCALATION CONTINUES IN RAS AND RAF MUTANT CA...
Více zde
IKENA ONCOLOGY REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND CORPORATE UPDATE
13-05-2024
STRONG FINANCIAL POSITION WITH $157.3 MILLION; RUNWAY INTO 2H 2026 IK-930 PROGRAM ON TRACK TO DELIVE...
Více zde
IKENA ONCOLOGY TO PRESENT AT THE STIFEL 2024 VIRTUAL TARGETED ONCOLOGY FORUM
10-04-2024
BOSTON, APRIL 10, 2024 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA,” “COMPA...
Více zde
IKENA ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
12-03-2024
IK-930 CONTINUES TO ADVANCE IN THE CLINIC NOW WITH AN OPTIMIZED FORMULATION WITH IMPROVED PHARMACOKI...
Více zde
IKENA ONCOLOGY TO PARTICIPATE IN TD COWEN 44TH ANNUAL HEALTH CARE CONFERENCE
27-02-2024
BOSTON, FEB. 27, 2024 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA,” “COMPAN...
Více zde
IKENA ONCOLOGY APPOINTS CAROLINE GERMA, M.D. AS CHIEF MEDICAL OFFICER
21-02-2024
CAROLINE GERMA, M.D., AN ACCOMPLISHED SENIOR EXECUTIVE AND MEDICAL ONCOLOGIST, BRINGS OVER 25 YEARS ...
Více zde
IKENA ONCOLOGY OUTLINES KEY PRIORITIES AND PROVIDES CORPORATE UPDATES
18-01-2024
IK-930 OPTIMIZED FORMULATION NOW IN THE CLINIC; ON TRACK TO DELIVER ADDITIONAL MONOTHERAPY DATA IN 2...
Více zde
IKENA ONCOLOGY SHARES INITIAL POSITIVE AND DIFFERENTIATED DOSE ESCALATION DATA FROM IK-930 PHASE I TRIAL AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
09-11-2023
FAVORABLE SAFETY PROFILE IN DOSE ESCALATION SHOWN TO DATE; SELECTIVE TEAD1 INHIBITION WITH IK-930 RE...
Více zde
IKENA ONCOLOGY TO PRESENT AT MULTIPLE NOVEMBER 2023 INVESTOR CONFERENCES
07-11-2023
BOSTON, NOV. 07, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA,” “COMPAN...
Více zde
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF AN INVESTIGATION CONCERNING POSSIBLE BREACHES OF FIDUCIARY DUTY BY CERTAIN OFFICERS AND DIRECTORS OF IKENA ONCOLOGY INC. (NASDAQ: IKNA)
02-10-2023
NEW YORK , OCT. 2, 2023 /PRNEWSWIRE/ -- LEVI & KORSINSKY ANNOUNCES THAT IT HAS COMMENCED AN INVESTIG...
Více zde
IKENA ONCOLOGY TO PARTICIPATE IN SEPTEMBER 2023 INVESTOR CONFERENCES
05-09-2023
BOSTON, SEPT. 05, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA,” “COMPA...
Více zde
IKENA ONCOLOGY REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND CORPORATE UPDATE
10-08-2023
INITIAL CLINICAL DATA FOR IK-930 MONOTHERAPY DOSE ESCALATION EXPECTED IN THE FOURTH QUARTER 2023 IK-...
Více zde
IKENA ONCOLOGY ACQUIRES PIONYR IMMUNOTHERAPEUTICS IN ALL-STOCK TRANSACTION
07-08-2023
IKENA RECEIVES APPROXIMATELY $43 MILLION IN NET CASH AT CLOSING NEW CAPITAL WILL FURTHER ACCELERATE ...
Více zde
IKENA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
24-05-2023
BOSTON, MAY 24, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA”), A TARGETE...
Více zde
IKENA ONCOLOGY REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND HIGHLIGHTS ADVANCEMENTS ACROSS TARGETED ONCOLOGY PIPELINE
15-05-2023
LEAD TARGETED ONCOLOGY PROGRAM IN HIPPO PATHWAY, IK-930, CONTINUES TO ADVANCE THROUGH DOSE ESCALATIO...
Více zde
IKENA ONCOLOGY ANNOUNCES $40 MILLION UNDERWRITTEN OFFERING
15-05-2023
BOSTON, MAY 15, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA”, “COMPAN...
Více zde
IKENA ONCOLOGY TO PARTICIPATE IN THE STIFEL 2023 VIRTUAL TARGETED ONCOLOGY DAYS
20-04-2023
BOSTON, APRIL 20, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA”), A TARGE...
Více zde
IKENA ONCOLOGY SHARES DIFFERENTIATION PROFILE OF IK-930, A NOVEL HIPPO-PATHWAY INHIBITOR, INCLUDING PROJECTED THERAPEUTIC INDEX ADVANTAGES AND BREADTH OF PATIENT POPULATIONS AT AACR 2023 ANNUAL MEETING
17-04-2023
IK-930 IS A POTENT HIPPO PATHWAY INHIBITOR THAT SELECTIVELY BINDS TEAD1 AND BROADLY REPRESSES ONCOGE...
Více zde
IKENA ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
14-03-2023
FOCUSED TARGETED ONCOLOGY PIPELINE ADVANCING TOWARDS MULTIPLE NEAR-TERM MILESTONES; RUNWAY INTO 2025...
Více zde
IKENA ONCOLOGY PRESENTS PRECLINICAL DATA ON IK-595, BEST-IN-CLASS NEXT-GENERATION MEK-RAF COMPLEX INHIBITOR, IN PLENARY SESSION AT AACR SPECIAL CONFERENCE ON RAS TARGETING
07-03-2023
BOSTON, MARCH 07, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA”), A TARGE...
Více zde
IKENA ONCOLOGY TO PARTICIPATE IN COWEN 43RD ANNUAL HEALTH CARE CONFERENCE
28-02-2023
BOSTON, FEB. 28, 2023 (GLOBE NEWSWIRE) -- IKENA ONCOLOGY, INC. (NASDAQ: IKNA, “IKENA”), A TARGET...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2025-12-18 00:00:00 | 8-K |  | Stáhnout |
| 2025-11-19 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2025-11-05 00:00:00 | 8-K | | Stáhnout |
| 2025-10-29 00:00:00 | 8-K | | Stáhnout |
| 2025-10-22 01:00:00 | 8-K | | Stáhnout |
| 2025-10-22 00:00:00 | 8-K | | Stáhnout |
| 2025-10-10 01:00:00 | 8-K | | Stáhnout |
| 2025-10-10 00:00:00 | 8-K | | Stáhnout |
| 2025-08-05 01:00:00 | 8-K | | Stáhnout |
| 2025-08-05 00:00:00 | 8-K | | Stáhnout |
| 2025-08-01 01:00:00 | 8-K | | Stáhnout |
| 2025-08-01 00:00:00 | 8-K | | Stáhnout |
| 2025-07-29 01:00:00 | 8-K | | Stáhnout |
| 2025-07-29 00:00:00 | 8-K | | Stáhnout |
| 2025-07-25 01:00:00 | 8-K | | Stáhnout |
| 2025-07-25 00:00:00 | 8-K | | Stáhnout |
| 2025-07-24 01:00:00 | 8-K | | Stáhnout |
| 2025-07-24 01:00:00 | 10-Q | | Stáhnout |
| 2025-07-24 00:00:00 | 8-K | | Stáhnout |
| 2025-07-24 00:00:00 | 10-Q | | Stáhnout |
| 2025-07-16 01:00:00 | 8-K | | Stáhnout |
| 2025-07-16 00:00:00 | 8-K | | Stáhnout |
| 2025-07-15 01:00:00 | 8-K | | Stáhnout |
| 2025-07-15 00:00:00 | 8-K | | Stáhnout |
| 2025-07-11 01:00:00 | 8-K | | Stáhnout |
| 2025-07-11 00:00:00 | 8-K | | Stáhnout |
| 2025-07-01 01:00:00 | 8-K | | Stáhnout |
| 2025-07-01 00:00:00 | 8-K | | Stáhnout |
| 2025-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2025-03-06 00:00:00 | 10-K | | Stáhnout |
| 2025-03-05 23:00:00 | 10-K | | Stáhnout |
| 2024-12-23 00:00:00 | 8-K | | Stáhnout |
| 2024-12-22 23:00:00 | 8-K | | Stáhnout |
| 2024-11-07 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-06 23:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-07-12 01:00:00 | 8-K | | Stáhnout |
| 2024-07-12 00:00:00 | 8-K | | Stáhnout |
| 2024-06-10 01:00:00 | 8-K | | Stáhnout |
| 2024-06-10 00:00:00 | 8-K | | Stáhnout |
| 2024-05-28 01:00:00 | 8-K | | Stáhnout |
| 2024-05-28 00:00:00 | 8-K | | Stáhnout |
| 2024-05-13 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-13 00:00:00 | 10-Q | | Stáhnout |
| 2024-03-12 00:00:00 | 10-K | | Stáhnout |
| 2024-03-11 23:00:00 | 10-K | | Stáhnout |
| 2024-02-21 00:00:00 | 8-K | | Stáhnout |
| 2024-02-20 23:00:00 | 8-K | | Stáhnout |
| 2024-01-18 00:00:00 | 8-K | | Stáhnout |
| 2024-01-17 23:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 8-K | | Stáhnout |
| 2023-11-09 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-08 23:00:00 | 8-K | | Stáhnout |
| 2023-11-08 23:00:00 | 10-Q | | Stáhnout |
| 2023-10-11 01:00:00 | 8-K | | Stáhnout |
| 2023-10-11 00:00:00 | 8-K | | Stáhnout |
| 2023-08-10 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-10 00:00:00 | 10-Q | | Stáhnout |
| 2023-08-07 01:00:00 | 8-K | | Stáhnout |
| 2023-08-07 00:00:00 | 8-K | | Stáhnout |
| 2023-06-30 01:00:00 | 8-K | | Stáhnout |
| 2023-06-30 00:00:00 | 8-K | | Stáhnout |
| 2023-06-09 01:00:00 | 8-K | | Stáhnout |
| 2023-06-09 00:00:00 | 8-K | | Stáhnout |
| 2023-05-15 01:00:00 | 8-K | | Stáhnout |
| 2023-05-15 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-15 00:00:00 | 8-K | | Stáhnout |
| 2023-05-15 00:00:00 | 10-Q | | Stáhnout |
| 2023-04-17 01:00:00 | 8-K | | Stáhnout |
| 2023-04-17 00:00:00 | 8-K | | Stáhnout |
| 2023-03-14 00:00:00 | 10-K | | Stáhnout |
| 2023-03-13 23:00:00 | 10-K | | Stáhnout |
| 2022-12-19 00:00:00 | 8-K | | Stáhnout |
| 2022-12-18 23:00:00 | 8-K | | Stáhnout |
| 2022-11-28 00:00:00 | 8-K | | Stáhnout |
| 2022-11-27 23:00:00 | 8-K | | Stáhnout |
| 2022-11-10 00:00:00 | 8-K | | Stáhnout |
| 2022-11-09 23:00:00 | 8-K | | Stáhnout |
| 2022-11-07 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-06 23:00:00 | 10-Q | | Stáhnout |
| 2022-08-11 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-11 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-10 01:00:00 | 8-K | | Stáhnout |
| 2022-06-10 00:00:00 | 8-K | | Stáhnout |
| 2022-05-12 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-12 00:00:00 | 10-Q | | Stáhnout |
| 2022-04-13 01:00:00 | 8-K | | Stáhnout |
| 2022-04-13 00:00:00 | 8-K | | Stáhnout |
| 2022-04-06 01:00:00 | 8-K | | Stáhnout |
| 2022-04-06 00:00:00 | 8-K | | Stáhnout |
| 2022-03-17 00:00:00 | 10-K | | Stáhnout |
| 2022-03-16 23:00:00 | 10-K | | Stáhnout |
| 2022-02-24 00:00:00 | 8-K | | Stáhnout |
| 2022-02-23 23:00:00 | 8-K | | Stáhnout |
| 2022-01-28 00:00:00 | 8-K | | Stáhnout |
| 2022-01-27 23:00:00 | 8-K | | Stáhnout |
| 2022-01-26 00:00:00 | 8-K | | Stáhnout |
| 2022-01-25 23:00:00 | 8-K | | Stáhnout |
| 2021-11-10 00:00:00 | 8-K | | Stáhnout |
| 2021-11-10 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-09 23:00:00 | 8-K | | Stáhnout |
| 2021-11-09 23:00:00 | 10-Q | | Stáhnout |
| 2021-08-12 01:00:00 | 8-K | | Stáhnout |
| 2021-08-12 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-12 00:00:00 | 8-K | | Stáhnout |
| 2021-08-12 00:00:00 | 10-Q | | Stáhnout |
| 2021-05-13 01:00:00 | 8-K | | Stáhnout |
| 2021-05-13 01:00:00 | 10-Q | | Stáhnout |
| 2021-05-13 00:00:00 | 8-K | | Stáhnout |
| 2021-05-13 00:00:00 | 10-Q | | Stáhnout |
| 2021-04-15 01:00:00 | 8-K | | Stáhnout |
| 2021-04-15 00:00:00 | 8-K | | Stáhnout |
| 2021-03-30 01:00:00 | 8-K | | Stáhnout |
| 2021-03-30 00:00:00 | 8-K | | Stáhnout |
